Haemostatix

Haemostatix is a biotechnology startup based in Nottingham, UK, co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The company aims to revolutionize bleeding management during surgeries, trauma cases, and leukemia treatment with its advanced peptide-based technology. Haemostatix has developed a unique peptide sequence that binds to fibrinogen, a crucial protein for clot formation, and combines it with various solid supports or soluble carriers to create both topical and systemic haemostats. The company's innovative technology platform underpins a pipeline of first-in-class products dedicated to treating various types of bleeding in surgical procedures, trauma situations, and for leukaemic patients. In November 2014, Haemostatix secured a £61.61K Venture Round investment from Albion Capital. With its focus on biotechnology and healthcare, Haemostatix is well-positioned to make a significant impact in the field of bleeding management, and its innovative approach has garnered the attention of investors looking to support groundbreaking solutions in the healthcare industry.